Published on 09 Sep 2021

Developing therapies for chronic wound healing

New therapy for chronic wounds

Scientists from NTU Singapore, the Skin Research Institute of Singapore (SRIS), and local biotech start-up Celligenics are working together to develop accessible and affordable therapies to accelerate healing in chronic wounds such as diabetic ulcers and bed sores.

Such chronic wounds typically afflict the elderly, who often have poor circulation in their lower limbs.  If left untreated, such wounds can lead to amputations, or even death if bacteria from the wound enters the bloodstream

The collaborative research effort, led by Professor David Becker, an expert on tissue repair and regeneration at NTU Singapore’s Lee Kong Chian School of Medicine (LKCMedicine) and at SRIS, will see the team of scientists formulating proof-of-concept wound healing patches, gels, or sprays using a regenerative extract developed by Celligenics, a spin-off from the Agency for Science, Technology and Research (A*STAR).

This regenerative extract is derived from stem cells obtained through Celligenics’ proprietary stem cell technology, which are able to stimulate cell repair. Preliminary data suggest a one-third acceleration in wound closure upon treating wounds with this extract,  highlighting the extract’s potential in addressing the needs of chronic wounds.

The prototypes developed by the NTU-SRIS-Celligenics team are being tested on a first-of-its-kind wound healing platform developed by SRIS, a tripartite partnership between A*STAR, the National Healthcare Group, and NTU.

Related media releases

Media coverage